Entrepreneur UK's London 100: Clays Bar
Since launching in 2021, Clays has redefined the status quo when it comes to experiential bars. Leveraging advanced motion-capture technology and using a deactivated shotgun, Clays delivers a fun and interactive gamified clay shooting experience with sub-millimetre accuracy.
2024 saw like for-like sales in its London venues up by over 25% compared to the previous year. In summer 2025 Clays will open its fourth UK site, in the heart of Central London, on Soho's Brewer Street. Alongside growth in the UK, Clays have confirmed global expansion into the US market.
Entering into a Joint Venture agreement with Hadrena, Clays have confirmed a roll out of 15 sites in the US. Clays expansion into the US market leads the next wave of British experiential leisure brands dominating in the US, following the success of Swingers, Puttshack and Electric Shuffle.
Clays founder, Tom Snellock, comments: "Our proprietary technology and international patents have allowed us to enter into the US market, whilst our Joint Venture agreement with Hadrena has enabled our rapid expansion plans into multiple US markets. With nothing quite like Clays in the current US market, we're confident in our potential for tremendous success across the Atlantic, paving the way to further build and strengthen our legacy."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
āshibio licences vantictumab for rare bone disorder
Biotechnology company āshibio has entered an exclusive licencing agreement with Mereo BioPharma for the monoclonal antibody, vantictumab, to treat a rare bone disorder. The agreement aims to facilitate antibody development for the autosomal dominant osteopetrosis type 2 (ADO2) bone condition that currently lacks approved therapies. āshibio will oversee clinical development of vantictumab globally for both adult and paediatric patients. Mereo has granted exclusive rights to āshibio for the development and commercialisation in the US and other regions outside of Europe, where Mereo retains commercial rights. ADO2, also referred to as Albers-Schönberg disease, is a genetic disorder characterised by reduced osteoclast function, leading to dense and brittle bones. It is linked to mutations in the chloride channel 7 (CLCN7) gene, with an incidence rate of one in 20,000 births. Āshibio CEO Pankaj Bhargava stated: 'People living with autosomal dominant osteopetrosis type 2 face a lifetime of bone-related complications resulting in significant morbidity, multiple surgical procedures, chronic pain and impaired quality of life – yet patients have no approved therapy to address the disease. 'Bringing vantictumab into our pipeline reflects our commitment to advancing therapies for rare skeletal conditions and improving the lives of those affected by serious bone disorders.' Vantictumab functions by selectively binding to specific frizzled (Fzd) receptors and inhibiting Wnt (wingless-related integration) signalling pathways. Initially developed for cancer treatment, it has undergone clinical trials in oncology showing a favourable safety and pharmacokinetic profile. Previous studies have generated biomarker data that support the efficacy of vantictumab on osteoclast function, which aids in reducing risks associated with the clinical programme and allows āshibio to expedite the advancement of vantictumab into clinical trials for ADO2. "āshibio licences vantictumab for rare bone disorder" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
3 minutes ago
- Yahoo
Oil Advances as Industry Data Points to US Inventory Decline
(Bloomberg) — Oil rose after an industry report signaled that US crude stockpiles declined last week, while traders assessed negotiations to end Russia's war against Ukraine. Brent futures (BZ=F) gained as much as 1.4% to trade above $66 a barrel in London, clawing back Tuesday's losses. The industry-funded American Petroleum Institute reported crude inventories fell by 2.4 million barrels last week, according to people familiar with the figures. Government data is due later Wednesday. Why New York City Has a Fleet of New EVs From a Dead Carmaker Chicago Schools Seeks $1 Billion of Short-Term Debt as Cash Gone Trump Takes Second Swing at Cutting Housing Assistance for Immigrants A Photographer's Pipe Dream: Capturing New York's Vast Water System A London Apartment Tower With Echoes of Victorian Rail and Ancient Rome Investors are watching on progress toward a ceasefire between Russia and Ukraine following a series of high-level talks brokered by President Donald Trump. Any eventual peace deal could lead to fewer restrictions on Russia's crude exports, although Moscow has largely kept its oil flowing despite an array of sanctions. A lot of that crude has been shipped to India since the war, drawing criticism from the Trump administration. On Tuesday, US Treasury Secretary Scott Bessent claimed on CNBC that some of the 'richest families in India' benefited from purchases of Russian oil, reiterating plans to boost tariffs on the South Asian nation. Bessent said on Fox News that the US is 'very happy' with its tariff arrangement with China, a sign that Washington will likely maintain status quo before a trade truce expires in November. Chinese refiners have also been big buyers of Russia oil, but Beijing hasn't faced the same criticism as India. The longer-term outlook for the oil market looks bearish, with expectations for a glut later in 2025 as OPEC+ returns barrels and as Trump's trade policies spark concerns about demand. Futures are down more than 10% this year. Foreigners Are Buying US Homes Again While Americans Get Sidelined What Declining Cardboard Box Sales Tell Us About the US Economy Women's Earnings Never Really Recover After They Have Children Survived Bankruptcy. Next Up: Cultural Relevance? Americans Are Getting Priced Out of Homeownership at Record Rates ©2025 Bloomberg L.P. Sign up for Yahoo Finance Daily Movers By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy
Yahoo
3 minutes ago
- Yahoo
City watch: UK back in fashion with US investors
Andrew Mann from highlights some stock market good news stories. Having returned from a sunny break in Provence, I find that stock markets are barely changed and continue to embrace a Goldilocks view of ongoing economic data, particularly in the US. So as not to ruin my holiday mood, I've been looking for good news stories and one in particular caught my eye. According to investment house Schroders, it seems to have been confirmed that the UK market is back in fashion, with US investors adding more than $15bn since the beginning of the year, a figure above that of any other overseas market. Often seen as a safe haven in the face of political and economic turbulence, relatively cheap valuations have finally started to catch the eye and this should come as welcome news to the LSE which, as readers will know, has struggled to attract new listings in recent years. Andrew Mann from JM Finn (Image: JM Finn) As Simon French at Panmure Liberum put it, perhaps this increasing attractiveness is no surprise considering some of the problems other countries have: the French can't pass a budget, the German economy has grown even slower than the UK, Canada is in the cross-hairs of the US trade war, and Japan has debt twice the size of the UK's! There was also good news from the UK economy, with second- quarter GDP rising by 0.3% - better than forecast but a slowdown from the 0.7% rise seen in the first quarter. Over the coming weeks investors will also be mindful of any possible peace dividend leading from a ceasefire between Ukraine and Russia should one materialise. The market odds on this happening have risen sharply since the Alaska summit was announced and a resolution would likely act as a tailwind for European equities, but to this writer, there seems an awfully long way to go yet. The value of securities and the income from them can fall as well as rise. Past performance should not be seen as an indicator of future returns. All views expressed are those of the author and should not be considered a recommendation or solicitation to buy or sell any products or securities.
